FAO's Animal Production and Health Division

Archives: Groupe de recherche

2002 Session of the Research Group of the Standing Technical Committee of EuFMD
Cesme, Izmir, Turkey 17-20 September 2002

Appendices
Rapport Complet (en anglais)
1. Update on the Global FMD Situation - See Map
2. Molecular epidemiological studies on recently-isolated FMD viruses - See Figure 1 - See Figure 2
3. FMD in Ireland; History, diagnosis, eradication and serosurveillance
4. Laboratory virological investigations relating to the 2001 FMD outbreak in the UK
5. Clinical and laboratory investigations of five outbreaks during the early stages of the 2001 FMD epidemic in the UK
6. The FMD epidemic in Dumfries and Galloway, Scotland in 2001
7. Swine vesicular disease in Italy during 2002: epidemiological and diagnostic aspects
8. The FMD disease situation in Turkey
9. A serosurvey following the Autumn 2001 FMD vaccination campaign in the Thrace region of Turkey
10. A serosurvey for antibodies to non-structural proteins of FMDV in the Thrace region of Turkey
11. Genetic characterisation of viruses of type O and A viruses isolated from Turkey between 2000 and 2002 See Figure
12. FMD control in endemic areas (Not available)
13. Modelling FMD: a comparison of epidemiological models
14. Problems in stamping-out and rendering practice: suggestions for improvements and alternatives
15. Culling versus vaccination: challenging a dogma in veterinary (FMD) science
16. Evaluation of acceptance of alternative FMD eradication strategies in Switzerland
17. Studies of quantitative parameters of virus excretion and transmission in pigs and cattle experimentally infected with FMD virus O UK 2001
18. Quantification and duration of FMD virus RNA in bovine oesophago-pharyngeal fluid as determined by realt-time RT-PCR
19. Modelling of viraemia in pigs infected with FMD virus
20. Expression of inflammatory and antiviral cytokines in pigs experimentally infected with FMD virus
21. FMD virus transmission between individually housed calves
22. Comparison of complete genomes of Asian, African and European isolates of a recent FMD virus type O pandemic strain (panAsia) - See Figure
23. Characterisation of monoclonal antibodies against FMD vaccine strain C1 Oberbayern and their reactivity with field isolates
24. Monoclonal antibodies against FMDV type Asia 1: preliminary characterisation and potential use in diagnostic assays
25. Diagnosis of FMD virus by automated RT-PCR
26. Comparison of RT-PCR procedures for diagnosis of clinical samples of FMD virus (serotypes O,A,C and Asia1) under the EU concerted action group project PL 98-4032
27. Diagnosis of A22 Mahmath and O1 Manisa FMD viruses from field samples: development of a latex agglutination test kit
28. FAO collaborative study Phase XVII: standardisation of FMD antibody detection - See Tables
29.Specific detection of antibodies against FMD by engineered b-galactosidase enzymatic sensors
30. Modification and further validation by different laboratories of a FMDV type O specific ELISA for detection of antibodies in all susceptible species
31. Comparison of ELISAs for the differentiation of infection from vaccination by detection of antibodies to the non-structural protein 3ABC of FMD virus - See Tables & Graphs 1 - See Tables & Graphs 2
32. Detection of IgG against the FMD virus non-structural polyprotein 3ABC in cattle and sheep - See Figures
33. A comparison of two 3ABC ELISAs in an African cattle population with endemic multiple serotype FMD
34. Recently generated data with the CHEKIT-FMD-3ABC ELISA kit and methods to monitor the operational performance of a 3ABC ELISA
35. Synthetic peptide based serosurveillance and vaccine system for FMD - See Tables
36. Regulation of FMD vaccines within the European Union
37. FMD vaccines: potency testing in the target species
38. Potency control of FMD vaccine in the field between 2001 and 2002
39. Monoclonal antibody based detection of 3A containing non-structural proteins in Al(OH)3 adjuvanted FMD vaccines
40. FMD in Argentina: development of vaccines for emergency control and eradication
41. Preparation of synthetic peptide vaccine with newly developed antigen-polymer conjugates as immunogen
42. Proposals for completion of Phase XVII and for Phase XVIII
43. List of Participants

COMMISSIONS

See also...

Archives: Groupe de recherche